Do you want to read an article? Please log in or register.
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial
Genitourinary Cancer
Related content
Genitourinary Cancer
Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis
Prostate Cancer Prostatic Dis
Creta M, Shariat SF, Marra G, Gontero P, Rossanese M, Morra S, Teoh J, Kishan AU, Karnes RJ, Longo N
doi: 10.1038/s41391-024-00883-3
Genitourinary Cancer
Focal therapy using high-intensity focused ultrasound with intraoperative prostate compression for patients with localized prostate cancer: a multi-center prospective study with 7 year experience
Prostate Cancer Prostatic Dis
Shoji S, Naruse J, Ohno S, Aoki M, Takahashi K, Yuzuriha S, Kuroda S, Umemoto T, Nakajima N, Hasegawa M, Kawamura Y, Kajiwara H, Hashida K, Uemura K, Hasebe T, Tajiri T
doi: 10.1038/s41391-024-00921-0
Breast Cancer
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial
JAMA Oncol
Dieci MV, Bisagni G, Bartolini S, Schirone A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Piacentini F, Orvieto E, Sanders M, Miglietta F, Massa D, Balduzzi S, Conte P, D'Amico R, Guarneri V
doi: 10.1001/jamaoncol.2024.6872
RECOMMENDED
Breast Cancer
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial
★ 2
Recommended by
Dr Andreas Müller, Faculty Member
Lancet Oncol
Kirby AM, Finneran L, Griffin CL, Brunt AM, Cafferty FH, Alhasso A, Chan C, Haviland JS, Jefford ML, Sawyer EJ, Sydenham MA, Syndikus I, Tsang YM, Wheatley D, Yarnold JR, Coles CE, Bliss JM
doi: 10.1016/S1470-2045(25)00194-9
Genitourinary Cancer
Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial
Eur Urol
Kishan AU, Lamb JM, Wilhalme H, Casado M, Chong N, Zello L, Juarez JE, Jiang T, Neilsen BK, Low DA, Yang Y, Neylon J, Basehart V, Martin Ma T, Valle LF, Cao M, Steinberg ML
doi: 10.1016/j.eururo.2024.10.026
Genitourinary Cancer
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
N Engl J Med
van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Camilleri P, Kancherla K, Frew J, Chan A, Naismith O, Armstrong J, Staffurth J, Martin A, Dayes I, Wells P, Price D, Williamson E, Pugh J, Manning G, Brown S, Burnett S, Hall E
doi: 10.1056/NEJMoa2403365
Genitourinary Cancer
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
Eur Urol
Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ
doi: 10.1016/j.eururo.2024.08.021
Genitourinary Cancer
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium
Lancet Oncol
Kishan AU, Sun Y, Tree AC, Hall E, Dearnaley D, Catton CN, Lukka HR, Pond G, Lee WR, Sandler HM, Feng FY, Nguyen PL, Incrocci L, Heemsbergen W, Pos FJ, Horwitz E, Wong JK, Hoffman KE, Hassanzadeh C, Kuban DA, Arcangeli S, Sanguineti G, Supiot S, Crehange G, Latorzeff I, Kalbasi TR, Steinberg ML, Valle LF, Loblaw A, Nikitas J, Roy S, Zaorsky NG, Jia AY, Spratt DE
doi: 10.1016/S1470-2045(25)00034-8
Genitourinary Cancer
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Lancet Oncol
Fay AP, Fizazi K, Matsubara N, Azad AA, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Cislo P, Chang J, Healy CG, Niyazov A, Agarwal N
doi: 10.1016/S1470-2045(25)00031-2